Nyrada, Inc. · ASX:NYR
Nyrada — Investor Presentation (November 2024)
20 slides from Nyrada's investor presentation, Nov 25, 2024
Slide 1: Investor Presentation November 2024
For personal use only Investor Presentation November 2024 Improving Lives, Offering Hope ASX:NYR Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should not be Such forward-looking statements do not guarantee of future performance and involve known considered as an offer or invitation to subscribe for, or purchase any securities in NYR,
Slide 3: About Nyrada
About Nyrada › Drug discovery and development company specialising in rational design of novel small molecule therapeutics. For personal use only › Nyrada’s lead drug candidate NYR-BI03: › demonstrated strong preclinical efficacy protecting the brain from secondary injury following stroke. › demonst
Slide 4: A Solid Foundation
A Solid Foundation For personal use only › Third generation TRPC ion channel blocker, using rational drug design. › Underlying target proven in mouse knock-out model. › Novel mechanism of action. › Unmet clinical need. No FDA approved drugs. › Significant target markets. › Completed preclinical safe
Slide 5: One Drug, Two Applications, Three Markets
One Two Three Drug Applications Markets For personal use only STROKE NYR-BI03 Neuroprotection Commencing ~US$52.2 billion by 20302 Phase Ia clinical trial in late CY2024 TRAUMATIC BRAIN INJURY ~US$5.5 billion by 20304 Cardioprotection MYOCARDIAL INFARCTION ~US$3.7 billion by 20325 5
Slide 6: Drug Development Cycle
Drug Development Cycle For personal use only Discovery & Preclinical Clinical FDA Post-market Development research trials review safety monitoring Scientists study how Once promising If the compounds After clinical trials, After a drug is a disease affects compounds are pass preclinical tests, the c
Slide 7: NYR-BI03 – Path to the Clinic
NYR-BI03 – Path to the Clinic For personal use only Completed In Progress ✓ 42% neuroprotective in ➢ Penetrative TBI efficacy stroke study ✓ 86% cardioprotective in ➢ HREC submission ischemia-reperfusion lodgement for Phase Ia injury ✓ Safety and toxicology testing 7
Slide 8: Indicative Phase I Study Design
Indicative Phase I Study Design For personal use only OBJECTIVES To assess the safety, tolerability, and pharmacokinetics of NYR-BI03 DESIGN • Randomised, double-blind PARTICIPANTS placebo –controlled, dose escalation design • Male and female healthy volunteers • 5 cohorts; 8 participants each • 18
Slide 9: TRPC Channel Blocking
TRPC Channel Blocking Activation following injury results For personal use only • in calcium entry via TRPC ion channels • Excessive calcium build-up leads to cell death • Blocking TRPC 3/6/7 ion channels is neuro- and cardio- protective Organ Cell Type TRPC Activation Effect NYR-BI03 Inhibition Eff
Slide 10: Cardioprotection
Cardioprotection Key Preclinical Results: NYR-BI03 showed strong For personal use only efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion (IR) injury • 86% Cardioprotection • 43% increase in left ventricular ejection fraction • 50% increase in fractional shortenin
Slide 11: Large Market Opportunity – Myocardial Infarction
Large Market Opportunity – Myocardial Infarction For personal use only Globally: ~15-20 million ~15% people suffer heart mortality within 30 attack annually days No current FDA approved treatments targeting myocardial infarction-reperfusion injury Effective treatment will improve patient outcomes an
Slide 12: Neuroprotection – Stroke and TBI
Neuroprotection – Stroke and TBI Serial reconstruction from MRI For personal use only Secondary Disability Primary Injury Injury Level 30 mins BECAME STAYED THE DIED WORSE SAME IMPROVED 72 hours Hours Days Weeks Months Reduce secondary injury resulting from stroke or TBI Nyrada drug NYR-BI03 • Impro
Slide 13: Large Market Opportunity – Stroke
Large Market Opportunity – Stroke For personal use only Globally: ~15 million ~5 million people suffer left permanently strokes annually1 disabled1 One approved drug class for stroke suitable for <15% of patients (tPA - tissue plasminogen activator). Effective treatment will improve patient outcomes
Slide 14: Large Market Opportunity – Traumatic Brain Injury (TBI)
Large Market Opportunity – Traumatic Brain Injury (TBI) For personal use only Globally: ~5.5 million ~55 million people suffer severe living with effects of TBA annually3 medically treated TBI3 No current FDA approved treatments Effective treatment will improve patient outcomes and reduce high costs
Slide 15: Vision and Strategy
Vision and Strategy For personal use only Our Vision: • to become a high-growth pharmaceutical company specialising in the discovery and development of novel treatments Our Strategy: • to develop treatments for diseases where there is an unmet clinical need, or where current treatments are suboptima
Slide 16: Nyrada's Lead Drug Candidate NYR-BI03
Nyrada’s Lead Drug Candidate NYR-BI03 For personal use only First-in-Class with Novel Significant Unmet Clinical Need Mechanism of Action and Market Opportunity › NYR-BI03 is a first-in-class therapy. › Targeting multiple indications. › Novel mechanism of action. › Stroke, TBI and ischemia- Reperfus
Slide 17: Cash and Capital
Cash and Capital For personal use only › Cash balance of AU$2.98 million at 30 September 2024 › Expected R&D rebate of AU$1.38 million subject to Government Agency Review › AU$3.36 million (before costs) in new equity capital raised in October 2024. › Target AU$1.00 million (before costs) SPP to clo
Slide 18: Conclusion
Conclusion › Summary For personal use only › Pioneering TRPC channel blocking therapies. › First-in-class neuroprotection and cardioprotection therapy with novel mode of action. › One drug asset targeting two significant therapeutic areas and three large markets. › News Flow › Late CY2024 - NYR-BI03
Slide 19: References
References 1 – World Health Organization - https://www.emro.who.int/health-topics/stroke-cerebrovascular- For personal use only accident/index.html#:~:text=Annually%2C%2015%20million%20people%20worldwide,cause%20i s%20high%20blood%20pressure 2 – Databridge Market Research - https://www.databridgemar
Slide 20: For personal use only
For personal use only @nyrada_inc @nyrada_inc info@nyrada.com www.nyrada.com 20